Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.85 |
| ▸ | NPC1 | O15118 | 8/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | MMP9 | P14780 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429748 | 0.92 | PABPC1 (1.00) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL6978685 | 0.92 | PABPC1 (1.00) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL14082581 | 0.90 | PABPC1 (0.69) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL4428905 | 0.90 | TRPV1 (0.76) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL14082279 | 0.89 | PABPC1 (0.79) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL774681 | 0.88 | PABPC1 (0.65) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL19631378 | 0.86 | PABPC1 (0.80) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL29647732 | 0.86 | PABPC1 (0.80) | PABPC1NPC1RAB9APOLBMMP9 | |
| SCHEMBL5661569 | 0.86 | NPC1 (0.81) | PABPC1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL14083563 | 0.84 | PABPC1 (0.67) | PABPC1NPC1RAB9APOLBMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480954-B1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | PABPC1 3444/4885NPC1 784/4885RAB9A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.